Healing & Recovery Peptides
Research peptides studied for tissue repair, wound healing, and recovery. Includes BPC-157, TB-500/Thymosin Beta-4, GHK-Cu, KPV, and LL-37 with evidence tiers and peer-reviewed citations.
This category covers peptides that have been studied in preclinical and early clinical research for their roles in tissue repair, angiogenesis, anti-inflammation, and accelerated recovery. Most compounds in this category remain at the preclinical stage, though several have shown promising results in animal models and small pilot studies.
Evidence Note: Most healing peptides are classified as preclinical. BPC-157 has limited pilot study data in humans. None are FDA-approved for therapeutic use as of 2026. All information is sourced from peer-reviewed literature.
BPC-157 (Body Protection Compound-157)
Evidence Tier: Preclinical / Limited Pilot Data — BPC-157 is a 15-amino acid pentadecapeptide derived from a protein found in human gastric juice. It has been extensively studied in animal models for tissue repair, cytoprotection, and wound healing.
TB-500 (Thymosin Beta-4 Fragment)
Evidence Tier: Preclinical / Phase I Safety — TB-500 is a synthetic fragment of Thymosin Beta-4, a 43-amino acid protein naturally produced by the thymus. It plays key roles in actin regulation, cell migration, and tissue repair.
GHK-Cu (Copper Tripeptide)
Evidence Tier: Preclinical (injectable) / Limited Human (topical) — GHK-Cu is a naturally occurring copper-binding tripeptide (Gly-His-Lys-Cu) found in human plasma. Plasma levels decline from ~200 ng/mL at age 20 to ~80 ng/mL at age 60.
KPV (Lysine-Proline-Valine)
Evidence Tier: Preclinical — KPV is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) with potent anti-inflammatory properties. Under FDA review for 2026 reclassification.
LL-37 (Cathelicidin)
Evidence Tier: Preclinical — LL-37 is the only human cathelicidin antimicrobial peptide. A 37-amino acid peptide with broad-spectrum antimicrobial activity and immunomodulatory properties.